LAURUSLABS.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (14 May 2024 @ 05:59):

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally...

Stats
Today's Volume	436 235
Average Volume	2.20M
Market Cap	233.80B
EPS	INR0 ( 2024-04-24 )
Next earnings date	( INR0 ) 2024-07-25
Last Dividend	INR1.200 ( 2023-05-10 )
Next Dividend	INR0 ( N/A )
P/E	145.57
ATR14	INR0.509 (0.12%)

Volume Correlation

Long: 0.20 (neutral)

Short: -0.67 (moderate negative)

Signal:(50.878) Neutral

Laurus Labs Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Laurus Labs Limited Correlation - Currency/Commodity

-0.11
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.24
( neutral )

-0.50
( weak negative )

0.15
( neutral )

Laurus Labs Limited Financials

Annual	2023
Revenue:	INR50.41B
Gross Profit:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2023
Revenue:	INR50.41B
Gross Profit:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2022
Revenue:	INR60.41B
Gross Profit:	INR32.66B (54.07 %)
EPS:	INR14.69

FY	2022
Revenue:	INR48.89B
Gross Profit:	INR26.40B (54.01 %)
EPS:	INR15.42

Financial Reports:

No articles found.

Laurus Labs Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0.800 (N/A)	INR0 (N/A)	INR1.200 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Laurus Labs Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 8.03 - good (80.33%) | Divividend Growth Potential Score: 3.32 - Decrease likely (33.55%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.300	2017-07-06
Last Dividend	INR1.200	2023-05-10
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	INR7.40	--
Avg. Dividend % Per Year	0.35%	--
Score	2.97	--
Div. Sustainability Score	8.03
Div.Growth Potential Score	3.32
Div. Directional Score	5.68	--

Next Divdend (Est)
(2024-12-02)

INR1.329 Estimate 3.60 %

Dividend Stability

0.29 Very Poor

Dividend Score

2.97

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2017	INR0	0.00%
2018	INR0.300	0.30%
2019	INR0.300	0.39%
2020	INR1.300	1.77%
2021	INR2.00	0.57%
2022	INR2.00	0.38%
2023	INR1.200	0.32%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUPRIYA.NS	Dividend Junior	2023-09-15	Annually	3	0.10%
NBIFIN.NS	Dividend Junior	2023-08-11	Sporadic	8	0.01%
HONDAPOWER.NS	Dividend Junior	2023-08-03	Annually	22	0.75%
CAREERP.NS	Dividend Junior	2023-09-21	Annually	11	0.68%
RPPL.NS	Dividend Junior	2023-08-24	Annually	6	0.31%
LICHSGFIN.NS	Dividend Junior	2023-08-18	Annually	23	1.85%
GABRIEL.NS	Dividend Knight	2023-08-07	Semi-Annually	20	0.71%
APOLLO.NS	Dividend Junior	2023-09-22	Annually	7	0.79%
TECHNOE.NS	Dividend Junior	2023-09-15	Annually	16	1.13%
OMINFRAL.NS	Dividend Junior	2023-09-22	Annually	13	0.78%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0318	1.500	9.36	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0191	1.200	9.36	10.00	[0 - 0.3]
returnOnEquityTTM	0.0396	1.500	-0.672	-1.007	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.232	0.800	8.84	7.07	[1 - 3]
quickRatioTTM	0.584	0.800	-1.272	-1.017	[0.8 - 2.5]
cashRatioTTM	0.0455	1.500	-0.858	-1.287	[0.2 - 2]
debtRatioTTM	0.300	-1.500	5.00	-7.50	[0 - 0.6]
interestCoverageTTM	2.19	1.000	-0.300	-0.300	[3 - 30]
operatingCashFlowPerShareTTM	10.46	2.00	6.51	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.46	2.00	4.77	9.54	[0 - 20]
debtEquityRatioTTM	0.612	-1.500	7.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.465	1.000	5.58	5.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0795	1.000	-0.410	-0.410	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.224	1.000	9.86	9.86	[0.2 - 2]
assetTurnoverTTM	0.601	0.800	9.33	7.46	[0.5 - 2]
Total Score				8.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	145.64	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0396	2.50	-0.432	-1.007	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.46	2.00	6.51	9.54	[0 - 30]
dividendYielPercentageTTM	0.277	1.500	3.07	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.46	2.00	6.51	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-30.76	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.112	1.000	9.70	0	[0.1 - 0.5]
Total Score				3.32

Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.